35Pharma Recognized as “Promising Biotech Company of the Year” by BIOTECanada.

Financing led by Frazier Life Sciences with participation from new investors including Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors and Columbia Threadneedle.

HS235 is a first-in-class Activin and GDF ligand trap that leads to fat-selective weight loss in vivo.

HS235 is a first-in-class Activin and GDF ligand trap that leads to fat-selective weight loss in vivo.

Guy Braunstein, MD, PhD is an experienced CMO who previously led global clinical development at multiple Pharma and biotech companies, including as Head of Global Clinical Development at Actelion until its $30 billion acquisition.